Last 12 months
Inside the activity.
0 purchase rows · 19 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 3 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 3 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 8 |
| Sep 2026 | 0 | 5 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 03, 2026 Filed Sep 3, 2026 22:29 UTC |
Sanzone Virginia RuthVP, General Counsel
|
SaleCommon Stock | 692 | $171.52 | $118,688.38 |
DisclosureSEC source: 0001669639-26-000004 · edgardoc.xml · nonDerivative · entry 4 Sanzone Virginia Ruth · CIK 0001669639 · VP, General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,604 F1 · shares: The restricted award sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 8, 2026. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $170.775 to $171.69, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| September 03, 2026 Filed Sep 3, 2026 22:29 UTC |
Sanzone Virginia RuthVP, General Counsel
|
SaleCommon Stock | 724 | $169.53 | $122,736.46 |
DisclosureSEC source: 0001669639-26-000004 · edgardoc.xml · nonDerivative · entry 3 Sanzone Virginia Ruth · CIK 0001669639 · VP, General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,296 F1 · shares: The restricted award sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 8, 2026. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $169.5 to $169.665, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| September 03, 2026 Filed Sep 3, 2026 22:29 UTC |
Sanzone Virginia RuthVP, General Counsel
|
SaleCommon Stock | 1,238 | $168.44 | $208,522.78 |
DisclosureSEC source: 0001669639-26-000004 · edgardoc.xml · nonDerivative · entry 2 Sanzone Virginia Ruth · CIK 0001669639 · VP, General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,020 F1 · shares: The restricted award sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 8, 2026. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $168.21 to $169.15, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| September 03, 2026 Filed Sep 3, 2026 22:29 UTC |
Sanzone Virginia RuthVP, General Counsel
|
SaleCommon Stock | 2,202 | $167.67 | $369,202.73 |
DisclosureSEC source: 0001669639-26-000004 · edgardoc.xml · nonDerivative · entry 1 Sanzone Virginia Ruth · CIK 0001669639 · VP, General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,258 F1 · shares: The restricted award sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 8, 2026. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $167.20 to $168.145, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| September 01, 2026 Filed Sep 1, 2026 21:21 UTC |
Bonnell Brian MichaelChief Financial Officer
|
SaleCommon Stock | 6,381 | $175.00 | $1,116,675.00 |
DisclosureSEC source: 0001804831-26-000006 · edgardoc.xml · nonDerivative · entry 1 Bonnell Brian Michael · CIK 0001804831 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,062 F1 · shares: The restricted award sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2026. F2 · price: All shares sold were sold at the exact price disclosed. Read SEC document |
| August 31, 2026 Filed Aug 31, 2026 20:43 UTC |
Bonnell Brian MichaelChief Financial Officer
|
SaleCommon Stock | 1,113 | $173.91 | $193,566.73 |
DisclosureSEC source: 0001804831-26-000005 · edgardoc.xml · nonDerivative · entry 4 Bonnell Brian Michael · CIK 0001804831 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,443 F1 · shares: The restricted award sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2026. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $173.77 to $174.08, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| August 31, 2026 Filed Aug 31, 2026 20:43 UTC |
Bonnell Brian MichaelChief Financial Officer
|
SaleCommon Stock | 4,568 | $173.44 | $792,290.82 |
DisclosureSEC source: 0001804831-26-000005 · edgardoc.xml · nonDerivative · entry 3 Bonnell Brian Michael · CIK 0001804831 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,556 F1 · shares: The restricted award sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2026. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $172.69 to $173.765, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| August 31, 2026 Filed Aug 31, 2026 20:43 UTC |
Bonnell Brian MichaelChief Financial Officer
|
SaleCommon Stock | 1,914 | $172.12 | $329,442.66 |
DisclosureSEC source: 0001804831-26-000005 · edgardoc.xml · nonDerivative · entry 2 Bonnell Brian Michael · CIK 0001804831 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,124 F1 · shares: The restricted award sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2026. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $171.625 to $172.6, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| August 31, 2026 Filed Aug 31, 2026 20:43 UTC |
Bonnell Brian MichaelChief Financial Officer
|
SaleCommon Stock | 1,712 | $171.05 | $292,843.08 |
DisclosureSEC source: 0001804831-26-000005 · edgardoc.xml · nonDerivative · entry 1 Bonnell Brian Michael · CIK 0001804831 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,038 F1 · shares: The restricted award sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2026. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $170.57 to $171.495, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| August 13, 2026 Filed Aug 13, 2026 22:56 UTC |
Woolson DanielVP, GM-Infusion Capital
|
SaleCommon Stock | 5,417 | $181.33 | $982,264.61 |
DisclosureSEC source: 0001698998-26-000004 · edgardoc.xml · nonDerivative · entry 1 Woolson Daniel · CIK 0001698998 · VP, GM-Infusion Capital 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,062 F1 · price: All shares sold were sold at the exact price disclosed. Read SEC document |
| August 12, 2026 Filed Aug 12, 2026 20:33 UTC |
Sousa BenChief Information Officer
|
SaleCommon Stock | 2,250 | $178.32 | $401,209.20 |
DisclosureSEC source: 0002013412-26-000003 · edgardoc.xml · nonDerivative · entry 1 Sousa Ben · CIK 0002013412 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,076 F1 · price: All shares sold were sold at the exact price disclosed. Read SEC document |
| August 11, 2026 Filed Aug 11, 2026 22:18 UTC |
Voigtlander Christian B.Chief Operating Officer
|
SaleCommon Stock | 8,929 | $182.93 | $1,633,404.29 |
DisclosureSEC source: 0001727477-26-000003 · edgardoc.xml · nonDerivative · entry 1 Voigtlander Christian B. · CIK 0001727477 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,377 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $182.85 to $183.03, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| August 11, 2026 Filed Aug 11, 2026 21:59 UTC |
FINNEY ELISHA WDirector
|
SaleCommon Stock | 378 | $182.48 | $68,978.12 |
DisclosureSEC source: 0001217439-26-000002 · edgardoc.xml · nonDerivative · entry 1 FINNEY ELISHA W · CIK 0001217439 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,871 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $182.4808 to $182.5701, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| May 22, 2026 Filed May 22, 2026 19:47 UTC |
Woolson DanielPresident
|
SaleCommon Stock | 2,123 | $132.21 | $280,684.80 |
DisclosureSEC source: 0001698998-26-000003 · primary_doc.xml · nonDerivative · entry 1 Woolson Daniel · CIK 0001698998 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,479 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.03 to $132.33, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| May 14, 2026 Filed May 15, 2026 16:19 UTC |
Sanzone Virginia RuthVP, General Counsel
|
SaleCommon Stock | 2,447 | $124.08 | $303,623.76 |
DisclosureSEC source: 0001669639-26-000003 · edgardoc.xml · nonDerivative · entry 1 Sanzone Virginia Ruth · CIK 0001669639 · VP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,460 F1 · price: All shares sold were sold at the exact price disclosed. Read SEC document |
| May 13, 2026 Filed May 14, 2026 01:29 UTC |
KENNEDY KOLLEEN TDirector
|
GrantCommon Stock · Derivative | 1,475 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001531738-26-000001 · primary_doc.xml · derivative · entry 3 KENNEDY KOLLEEN T · CIK 0001531738 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,475 Underlying: Common Stock · 1,475 shares Expires 2027-05-13 F1 · security: These securities are Restricted Stock Units. F2 · derivative.exercise_price: There is neither a purchase price nor an exercise price for Restricted Stock Units. F3 · derivative.exercise_date: These awards vest on the anniversary of the date of the grant or the following annual stockholder meeting, whichever occurs first. Read SEC document |
| May 13, 2026 Filed May 14, 2026 01:29 UTC |
KENNEDY KOLLEEN TDirector
|
Exercise / conversionCommon Stock · Derivative | 1,254 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001531738-26-000001 · primary_doc.xml · derivative · entry 2 KENNEDY KOLLEEN T · CIK 0001531738 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,254 shares Expires 2026-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: These securities are Restricted Stock Units. F2 · derivative.exercise_price: There is neither a purchase price nor an exercise price for Restricted Stock Units. F3 · derivative.exercise_date: These awards vest on the anniversary of the date of the grant or the following annual stockholder meeting, whichever occurs first. Read SEC document |
| May 13, 2026 Filed May 14, 2026 01:29 UTC |
KENNEDY KOLLEEN TDirector
|
Exercise / conversionCommon Stock | 1,254 | $0.00 | $0.00 |
DisclosureSEC source: 0001531738-26-000001 · primary_doc.xml · nonDerivative · entry 1 KENNEDY KOLLEEN T · CIK 0001531738 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,539 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: These securities are Restricted Stock Units. F2 · price: There is neither a purchase price nor an exercise price for Restricted Stock Units. Read SEC document |
| May 13, 2026 Filed May 14, 2026 01:20 UTC |
Hernandez LaurieDirector
|
GrantCommon Stock · Derivative | 1,475 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001871884-26-000001 · primary_doc.xml · derivative · entry 3 Hernandez Laurie · CIK 0001871884 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,475 Underlying: Common Stock · 1,475 shares Expires 2027-05-13 F1 · security: These securities are Restricted Stock Units. F2 · derivative.exercise_price: There is neither a purchase price nor an exercise price for the Restricted Stock Units. F3 · derivative.exercise_date: These awards vest on the anniversary of the date of the grant or the following stockholder meeting, whichever occurs first. Read SEC document |
| May 13, 2026 Filed May 14, 2026 01:20 UTC |
Hernandez LaurieDirector
|
Exercise / conversionCommon Stock · Derivative | 1,254 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001871884-26-000001 · primary_doc.xml · derivative · entry 2 Hernandez Laurie · CIK 0001871884 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,254 shares Expires 2026-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: These securities are Restricted Stock Units. F2 · derivative.exercise_price: There is neither a purchase price nor an exercise price for the Restricted Stock Units. F3 · derivative.exercise_date: These awards vest on the anniversary of the date of the grant or the following stockholder meeting, whichever occurs first. Read SEC document |
| May 13, 2026 Filed May 14, 2026 01:20 UTC |
Hernandez LaurieDirector
|
Exercise / conversionCommon Stock | 1,254 | $0.00 | $0.00 |
DisclosureSEC source: 0001871884-26-000001 · primary_doc.xml · nonDerivative · entry 1 Hernandez Laurie · CIK 0001871884 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,862 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: These securities are Restricted Stock Units. F2 · price: There is neither a purchase price nor an exercise price for the Restricted Stock Units. Read SEC document |
| May 13, 2026 Filed May 14, 2026 01:11 UTC |
FINNEY ELISHA WDirector
|
GrantCommon Stock · Derivative | 1,475 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001217439-26-000001 · primary_doc.xml · derivative · entry 3 FINNEY ELISHA W · CIK 0001217439 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,475 Underlying: Common Stock · 1,475 shares Expires 2027-05-13 F1 · security: These securities are Restricted Stock Units. F2 · derivative.exercise_price: There is neither a purchase price nor an exercise price for the Restricted Stock Units. F3 · derivative.exercise_date: These awards vest on the anniversary of the date of the grant or the following annual stockholder meeting, whichever occurs first. Read SEC document |
| May 13, 2026 Filed May 14, 2026 01:11 UTC |
FINNEY ELISHA WDirector
|
Exercise / conversionCommon Stock · Derivative | 1,254 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001217439-26-000001 · primary_doc.xml · derivative · entry 2 FINNEY ELISHA W · CIK 0001217439 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,254 shares Expires 2026-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: These securities are Restricted Stock Units. F2 · derivative.exercise_price: There is neither a purchase price nor an exercise price for the Restricted Stock Units. F3 · derivative.exercise_date: These awards vest on the anniversary of the date of the grant or the following annual stockholder meeting, whichever occurs first. Read SEC document |
| May 13, 2026 Filed May 14, 2026 01:11 UTC |
FINNEY ELISHA WDirector
|
Exercise / conversionCommon Stock | 1,254 | $0.00 | $0.00 |
DisclosureSEC source: 0001217439-26-000001 · primary_doc.xml · nonDerivative · entry 1 FINNEY ELISHA W · CIK 0001217439 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,249 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: These securities are Restricted Stock Units. F2 · price: There is neither a purchase price nor an exercise price for the Restricted Stock Units. Read SEC document |
| May 13, 2026 Filed May 14, 2026 00:52 UTC |
Abbey DonaldDirector
|
GrantCommon Stock · Derivative | 1,475 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001534342-26-000008 · primary_doc.xml · derivative · entry 3 Abbey Donald · CIK 0001534342 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,475 Underlying: Common Stock · 1,475 shares Expires 2027-05-13 F1 · security: These securities are Restricted Stock Units. F2 · derivative.exercise_price: There is neither a purchase price nor an exercise price for the Restricted Stock Units. F3 · derivative.exercise_date: These awards vest on the anniversary of the date of the grant or the following annual stockholder meeting, whichever occurs first. Read SEC document |
| May 13, 2026 Filed May 14, 2026 00:52 UTC |
Abbey DonaldDirector
|
Exercise / conversionCommon Stock · Derivative | 1,254 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001534342-26-000008 · primary_doc.xml · derivative · entry 2 Abbey Donald · CIK 0001534342 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,254 shares Expires 2027-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: These securities are Restricted Stock Units. F2 · derivative.exercise_price: There is neither a purchase price nor an exercise price for the Restricted Stock Units. F3 · derivative.exercise_date: These awards vest on the anniversary of the date of the grant or the following annual stockholder meeting, whichever occurs first. Read SEC document |
| May 13, 2026 Filed May 14, 2026 00:52 UTC |
Abbey DonaldDirector
|
Exercise / conversionCommon Stock | 1,254 | $0.00 | $0.00 |
DisclosureSEC source: 0001534342-26-000008 · primary_doc.xml · nonDerivative · entry 1 Abbey Donald · CIK 0001534342 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,004 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: These securities are Restricted Stock Units. Read SEC document |
| May 13, 2026 Filed May 14, 2026 00:31 UTC |
Greenberg David C.Director
|
GrantCommon Stock · Derivative | 1,475 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001645866-26-000001 · primary_doc.xml · derivative · entry 6 Greenberg David C. · CIK 0001645866 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,475 Underlying: Common Stock · 1,475 shares Expires 2027-05-13 F2 · security: These securities are Restricted Stock Units. F3 · derivative.exercise_price: There is neither a purchase price nor an exercise price for the Restricted Stock Units. F4 · derivative.exercise_date: These awards vest on the anniversary date of the date of the grant or the following annual stockholder meeting, whichever occurs first. Read SEC document |
| May 13, 2026 Filed May 14, 2026 00:31 UTC |
Greenberg David C.Director
|
Exercise / conversionCommon Stock · Derivative | 1,254 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001645866-26-000001 · primary_doc.xml · derivative · entry 5 Greenberg David C. · CIK 0001645866 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,254 shares Expires 2026-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: These securities are Restricted Stock Units. F3 · derivative.exercise_price: There is neither a purchase price nor an exercise price for the Restricted Stock Units. F4 · derivative.exercise_date: These awards vest on the anniversary date of the date of the grant or the following annual stockholder meeting, whichever occurs first. Read SEC document |
| May 13, 2026 Filed May 14, 2026 00:31 UTC |
Greenberg David C.Director
|
Exercise / conversionCommon Stock | 1,254 | $0.00 | $0.00 |
DisclosureSEC source: 0001645866-26-000001 · primary_doc.xml · nonDerivative · entry 3 Greenberg David C. · CIK 0001645866 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,214 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: These securities are Restricted Stock Units. Read SEC document |
| May 13, 2026 Filed May 14, 2026 00:38 UTC |
Hoffmeister David FDirector
|
GrantCommon Stock · Derivative | 1,475 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001305975-26-000004 · edgardoc.xml · derivative · entry 3 Hoffmeister David F · CIK 0001305975 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,475 Underlying: Common Stock · 1,475 shares Expires 2027-05-13 F1 · security: These securities are Restricted Stock Units. F2 · derivative.exercise_price: There is neither a purchase price nor an exercise price for the Restricted Stock Units. F3 · derivative.exercise_date: These awards vest on the anniversary of the date of the grant or the following annual stockholder meeting, whichever occurs first. Read SEC document |
| May 13, 2026 Filed May 14, 2026 00:38 UTC |
Hoffmeister David FDirector
|
Exercise / conversionCommon Stock · Derivative | 1,254 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001305975-26-000004 · edgardoc.xml · derivative · entry 2 Hoffmeister David F · CIK 0001305975 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,254 shares Expires 2026-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: These securities are Restricted Stock Units. F2 · derivative.exercise_price: There is neither a purchase price nor an exercise price for the Restricted Stock Units. F3 · derivative.exercise_date: These awards vest on the anniversary of the date of the grant or the following annual stockholder meeting, whichever occurs first. Read SEC document |
| May 13, 2026 Filed May 14, 2026 00:38 UTC |
Hoffmeister David FDirector
|
Exercise / conversionCommon Stock | 1,254 | $0.00 | $0.00 |
DisclosureSEC source: 0001305975-26-000004 · edgardoc.xml · nonDerivative · entry 1 Hoffmeister David F · CIK 0001305975 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,004 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: These securities are Restricted Stock Units. Read SEC document |
| May 12, 2026 Filed May 14, 2026 00:31 UTC |
Greenberg David C.Director
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,424 | $0.00 Strike: $101.06 | $0.00 |
DisclosureSEC source: 0001645866-26-000001 · primary_doc.xml · derivative · entry 4 Greenberg David C. · CIK 0001645866 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,424 shares Expires 2026-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2026 Filed May 14, 2026 00:31 UTC |
Greenberg David C.Director
|
SaleCommon Stock | 2,424 | $122.91 | $297,933.84 |
DisclosureSEC source: 0001645866-26-000001 · primary_doc.xml · nonDerivative · entry 2 Greenberg David C. · CIK 0001645866 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,960 F1 · price: All shares sold were at the exact price disclosed. Read SEC document |
| May 12, 2026 Filed May 14, 2026 00:31 UTC |
Greenberg David C.Director
|
Exercise / conversionCommon Stock | 2,424 | $101.06 | $244,969.44 |
DisclosureSEC source: 0001645866-26-000001 · primary_doc.xml · nonDerivative · entry 1 Greenberg David C. · CIK 0001645866 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,384 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 25, 2026 Filed Mar 26, 2026 18:15 UTC |
Abbey DonaldDirector
|
OtherCommon Stock | 704 | $0.00 | $0.00 |
DisclosureSEC source: 0001534342-26-000007 · primary_doc.xml · nonDerivative · entry 1 Abbey Donald · CIK 0001534342 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,046 F1 · kind: Represents transfer of shares of common stock by the reporting person pursuant to a domestic relations order. The reporting person no longer has a reportable beneficial interest in the shares transferred. F1 · shares: Represents transfer of shares of common stock by the reporting person pursuant to a domestic relations order. The reporting person no longer has a reportable beneficial interest in the shares transferred. Read SEC document |
| March 15, 2026 Filed Mar 16, 2026 20:33 UTC |
Woolson DanielVP, GM-Infusion Capital
|
Exercise / conversionPerformance Shares · Derivative | 2,924 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001698998-26-000002 · edgardoc.xml · derivative · entry 3 Woolson Daniel · CIK 0001698998 · VP, GM-Infusion Capital 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,924 shares Expires 2026-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: These Securities are Performance-based Restricted Stock Units (PRSU). F2 · derivative.exercise_price: There is neither a purchase price nor an exercise price for the PRSUs. F3 · derivative.exercise_date: These PRSUs were granted on May 17, 2023. Vesting of these performance stock units are subject to the satisfaction of both performance-based conditions and time-based criteria. These PRSUs vest on March 15 of the first, second, and third year following the year of grant. Read SEC document |
| March 15, 2026 Filed Mar 16, 2026 20:33 UTC |
Woolson DanielVP, GM-Infusion Capital
|
Tax withholdingCommon Stock | 1,295 | $125.85 | $162,975.75 |
DisclosureSEC source: 0001698998-26-000002 · edgardoc.xml · nonDerivative · entry 2 Woolson Daniel · CIK 0001698998 · VP, GM-Infusion Capital 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,602 Read SEC document |
| March 15, 2026 Filed Mar 16, 2026 20:33 UTC |
Woolson DanielVP, GM-Infusion Capital
|
Exercise / conversionCommon Stock | 2,924 | $0.00 | $0.00 |
DisclosureSEC source: 0001698998-26-000002 · edgardoc.xml · nonDerivative · entry 1 Woolson Daniel · CIK 0001698998 · VP, GM-Infusion Capital 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,897 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: These Securities are Performance-based Restricted Stock Units (PRSU). Read SEC document |
| March 15, 2026 Filed Mar 16, 2026 20:34 UTC |
Voigtlander Christian B.Chief Operating Officer
|
Exercise / conversionPerformance Shares · Derivative | 11,400 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001727477-26-000002 · edgardoc.xml · derivative · entry 6 Voigtlander Christian B. · CIK 0001727477 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,400 shares Expires 2026-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: These Securities are Performance-based Restricted Stock Units (PRSU). F5 · derivative.exercise_price: There is neither a purchase price nor an exercise price for the PRSUs. F2 · shares: Represents the settlement of performance stock units granted on 3/15/2023. Upon the certification of performance results by the Compensation Committee on 2/11/26, the PRSUs were earned at 117% of target, resulting in the acquisition of the shares reported herein. Read SEC document |
| March 15, 2026 Filed Mar 16, 2026 20:34 UTC |
Voigtlander Christian B.Chief Operating Officer
|
Exercise / conversionCommon Stock · Derivative | 3,248 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001727477-26-000002 · edgardoc.xml · derivative · entry 5 Voigtlander Christian B. · CIK 0001727477 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,248 shares Expires 2026-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: These securities are Restricted Stock Units. F4 · derivative.exercise_price: There is neither a purchase price nor an exercise price for the Restricted Stock Units. Read SEC document |
| March 15, 2026 Filed Mar 16, 2026 20:34 UTC |
Voigtlander Christian B.Chief Operating Officer
|
Tax withholdingCommon Stock | 1,795 | $125.85 | $225,900.75 |
DisclosureSEC source: 0001727477-26-000002 · edgardoc.xml · nonDerivative · entry 4 Voigtlander Christian B. · CIK 0001727477 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,306 Read SEC document |
| March 15, 2026 Filed Mar 16, 2026 20:34 UTC |
Voigtlander Christian B.Chief Operating Officer
|
Exercise / conversionCommon Stock | 3,248 | $0.00 | $0.00 |
DisclosureSEC source: 0001727477-26-000002 · edgardoc.xml · nonDerivative · entry 3 Voigtlander Christian B. · CIK 0001727477 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,101 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: These securities are Restricted Stock Units. Read SEC document |
| March 15, 2026 Filed Mar 16, 2026 20:34 UTC |
Voigtlander Christian B.Chief Operating Officer
|
Tax withholdingCommon Stock | 6,301 | $125.85 | $792,980.85 |
DisclosureSEC source: 0001727477-26-000002 · edgardoc.xml · nonDerivative · entry 2 Voigtlander Christian B. · CIK 0001727477 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,853 Read SEC document |
| March 15, 2026 Filed Mar 16, 2026 20:34 UTC |
Voigtlander Christian B.Chief Operating Officer
|
Exercise / conversionCommon Stock | 11,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001727477-26-000002 · edgardoc.xml · nonDerivative · entry 1 Voigtlander Christian B. · CIK 0001727477 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,154 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: These Securities are Performance-based Restricted Stock Units (PRSU). F2 · shares: Represents the settlement of performance stock units granted on 3/15/2023. Upon the certification of performance results by the Compensation Committee on 2/11/26, the PRSUs were earned at 117% of target, resulting in the acquisition of the shares reported herein. Read SEC document |
| March 15, 2026 Filed Mar 16, 2026 20:30 UTC |
Jain VivekDirector · Chairman and CEO
|
Exercise / conversionPerformance Shares · Derivative | 17,100 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001410442-26-000002 · edgardoc.xml · derivative · entry 7 Jain Vivek · CIK 0001410442 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,100 shares Expires 2026-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: These Securities are Performance-based Restricted Stock Units (PRSU). F5 · derivative.exercise_price: There is neither a purchase price nor an exercise price for the PRSUs. F2 · shares: Represents the settlement of performance stock units granted on 3/15/2023. Upon the certification of performance results by the Compensation Committee on 2/11/26, the PRSUs were earned at 117% of target, resulting in the acquisition of the shares reported herein. Read SEC document |
| March 15, 2026 Filed Mar 16, 2026 20:30 UTC |
Jain VivekDirector · Chairman and CEO
|
Exercise / conversionCommon Stock · Derivative | 4,872 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001410442-26-000002 · edgardoc.xml · derivative · entry 6 Jain Vivek · CIK 0001410442 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,872 shares Expires 2026-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: These securities are Restricted Stock Units. F4 · derivative.exercise_price: There is neither a purchase price nor an exercise price for the Restricted Stock Units. Read SEC document |
| March 15, 2026 Filed Mar 16, 2026 20:30 UTC |
Jain VivekDirector · Chairman and CEO
|
Tax withholdingCommon Stock | 2,693 | $125.85 | $338,914.05 |
DisclosureSEC source: 0001410442-26-000002 · edgardoc.xml · nonDerivative · entry 4 Jain Vivek · CIK 0001410442 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,833 F3 · security: These securities are Restricted Stock Units. Read SEC document |
| March 15, 2026 Filed Mar 16, 2026 20:30 UTC |
Jain VivekDirector · Chairman and CEO
|
Exercise / conversionCommon Stock | 4,872 | $0.00 | $0.00 |
DisclosureSEC source: 0001410442-26-000002 · edgardoc.xml · nonDerivative · entry 3 Jain Vivek · CIK 0001410442 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,526 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: These securities are Restricted Stock Units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.